Monitoring Tumor Response to Linifanib Therapy with SPECT/CT Using the Integrin αvβ3–Targeted Radiotracer 99mTc-3P-RGD2 99mTc-3P-RGD2: An Integrin αvβ3–Targeted Radiotracer to Monitor Linifanib Therapy
Shundong Ji(Purdue University West Lafayette), Sarah R. Mudd(AbbVie (United States)), Guoqiang Shao(Nanjing Medical University), Yang Zhou(Chinese Academy of Sciences), Martin J. Voorbach(AbbVie (United States)), Yumin Zhang(Purdue University West Lafayette), Gerard B. Fox(Purdue University West Lafayette), Yanping Luo(Abbott Fund), Shuang Liu(Chongqing University), Daniel H. Albert(AbbVie (United States))
Cited by 26
Related Papers
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|776
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
|Science Translational Medicine|2015|541
Validation of Diacyl Glycerolacyltransferase I as a Novel Target for the Treatment of Obesity and Dyslipidemia Using a Potent and Selective Small Molecule Inhibitor
|Journal of Medicinal Chemistry|2008|140
“Kiss-and-Run” Glutamate Secretion in Cultured and Freshly Isolated Rat Hippocampal Astrocytes
|Journal of Neuroscience|2005|131